Q1 2024 EPS Estimates for OptimizeRx Co. Lowered by Analyst (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Analysts at William Blair lowered their Q1 2024 earnings per share estimates for shares of OptimizeRx in a note issued to investors on Tuesday, April 16th. William Blair analyst R. Daniels now forecasts that the company will post earnings of ($0.34) per share for the quarter, down from their prior forecast of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.57) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

Several other analysts have also issued reports on OPRX. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a research note on Monday, April 1st. JMP Securities reaffirmed a “market outperform” rating and issued a $15.00 target price on shares of OptimizeRx in a research note on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a research note on Monday, April 1st. Finally, Barclays assumed coverage on OptimizeRx in a research note on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.86.

OptimizeRx Trading Down 0.3 %

Shares of NASDAQ OPRX opened at $9.32 on Thursday. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65. The firm has a market capitalization of $169.44 million, a price-to-earnings ratio of -9.23 and a beta of 0.98. The business has a 50-day moving average of $13.24 and a 200-day moving average of $11.96.

Institutional Trading of OptimizeRx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kennedy Capital Management LLC bought a new stake in OptimizeRx in the third quarter valued at approximately $4,323,000. Jacob Asset Management of New York LLC raised its holdings in shares of OptimizeRx by 30.1% during the third quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock valued at $2,881,000 after acquiring an additional 85,720 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of OptimizeRx during the third quarter valued at approximately $162,000. Tower Research Capital LLC TRC raised its holdings in shares of OptimizeRx by 407.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,765 shares of the company’s stock valued at $97,000 after acquiring an additional 5,432 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of OptimizeRx during the third quarter valued at approximately $49,000. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.